Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
56actual
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-06 | actual | When the study began enrolling |
| Primary completion | 2026-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ALN-F1202
- Drug: Matching Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment Emergent Adverse Events (TEAEs)
measured Up to 190 Days
Severity of TEAEs
measured Up to 190 Days
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed